<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02387008</url>
  </required_header>
  <id_info>
    <org_study_id>13-2429</org_study_id>
    <nct_id>NCT02387008</nct_id>
  </id_info>
  <brief_title>Prospective, Comparative Assessment of Alveolar Bone Augmentation Using GUIDOR® Membrane in the Bound Edentulous Space</brief_title>
  <official_title>Prospective, Comparative Assessment of Alveolar Bone Augmentation Using Guidor Membrane in the Bound Edentulous Space</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunstar Americas</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: The goal of guided bone augmentation is to provide an alveolar ridge of sufficient
      dimension to permit dental implant placement. While a wide variety of bone graft and barrier
      membrane products are commercially available, limited evidence exists supporting the use of
      one technique over another. The purpose of this study is to radiographically define the
      dimensional bone changes following horizontal bone augmentation using a synthetic GUIDOR®
      (Sunstar, Inc.) membrane. Secondary outcome measurements will include the assessment of
      inflammation, infection, or other wound healing complications.

      Participants: A total of 60 patients requiring bone augmentation of a single bound edentulous
      site prior to dental implant placement will be selected for this study. This is a multicenter
      study with 30 patients receiving treatment at each study site.

      Procedures (methods): Patients will be randomly allocated to receive horizontal bone
      augmentation with synthetic GUIDOR® membrane + freeze dried bone augmentation (FDBA),
      synthetic GUIDOR® membrane alone, or xenograft BioGide® membrane + FDBA. Cone beam computed
      tomography (CBCT) imaging will be obtained at baseline and 6 months post-operatively to
      assess dimensional alveolar ridge changes. Additionally, post-operative appointments at 1, 2,
      and 4 weeks post-grafting will be completed to assess the presence of inflammation,
      infection, wound dehiscence, or membrane exposure.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was halted prematurely by UNC for low accrual.
  </why_stopped>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Actual">November 28, 2018</completion_date>
  <primary_completion_date type="Actual">November 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dimensional Bone Changes at 6 Months</measure>
    <time_frame>6 months after treatment</time_frame>
    <description>Dimensional bone changes will assessed by calculating horizontal width and vertical height changes using data from DICOM images acquired by Cone beam computed tomography (CBCT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>7 days, 14 days, 28 days, 6 months</time_frame>
    <description>The presence or absence of soft tissue erythema within 3 mm from the crestal incision in the edentulous site will be visually assessed at post-operative evaluations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>7 days, 14 days, 28 days, 6 months</time_frame>
    <description>The presence or absence of infection in the area of ridge augmentation will be assessed through visual evaluation and palpation. The presence of suppuration from the crestal incision or soft tissues adjacent to the localized ridge augmentation will be assessed through visual evaluation. Fluctuance in the area of the augmentation will be assessed through gentle palpation of the surgical site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Membrane Exposure</measure>
    <time_frame>7 days, 14 days, 28 days, 6 months</time_frame>
    <description>The presence of membrane exposure or soft tissue dehiscence will be visually assessed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Bone Regeneration</condition>
  <arm_group>
    <arm_group_label>GUIDOR® membrane with FDBA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GUIDOR® membrane alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>horizontal bone augmentation with synthetic GUIDOR® membrane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bio-Gide® membrane with FDBA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>xenograft BioGide® membrane + FDBA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GUIDOR® membrane with FDBA</intervention_name>
    <description>horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA</description>
    <arm_group_label>GUIDOR® membrane with FDBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GUIDOR® membrane</intervention_name>
    <description>horizontal bone augmentation with synthetic GUIDOR® membrane</description>
    <arm_group_label>GUIDOR® membrane alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bio-Gide® membrane with FDBA</intervention_name>
    <description>xenograft BioGide® membrane + FDBA</description>
    <arm_group_label>Bio-Gide® membrane with FDBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent

          2. ≥ 21 years and ≤ 75 years

          3. In need of one or more implants replacing missing or non-restorable teeth in the
             maxilla within region 14 to 24 or the mandible within region 34 to 44

          4. Edentulous for at least 6 months at study site

          5. A buccal-lingual ridge width at study site of ≤ 4 mm

          6. A mesial-distal distance between adjacent teeth at study site at bone level of at
             least 5 mm

          7. A keratinized mid-buccal mucosal thickness of at least 2 mm at study site (measured
             buccally at MD midline from the mucogingival junction to the projected alveolar ridge
             crest)

          8. Teeth adjacent (mesial and distal) to study site must consist of two stable, natural
             teeth without signs of periodontal bone loss (&gt; 3 mm) and/or significant soft tissue
             loss

          9. A minimum of twenty teeth in good repair

        Exclusion Criteria:

          1. Insufficient interocclusal distance for implant placement and restoration at study
             site

          2. More than 3 mm vertical bone loss at study site as measured from the mid-buccal crest
             of bone on the adjacent teeth

          3. Previous site development (soft and/or bone tissue) performed at the study site

          4. Untreated rampant caries and uncontrolled periodontal disease

          5. A history within the last 6 months of the daily use of any non-cigarette tobacco
             products (smokeless chewing tobacco, e-cigarette, pipe or cigar smoking), or of
             smoking more than 10 cigarettes per day.

          6. Current alcohol dependency, alcohol abuse or chemical dependency based on DSM-IV
             Criteria or drug abuse

          7. Subjects having uncontrolled endocrine-induced diseases (e.g. uncontrolled diabetes
             mellitus)

          8. Systemic or local disease or condition that would compromise post-operative healing
             and/or osseointegration

          9. Use of any substance or medication that will influence bone metabolism (e.g.
             intravenous bisphosphonates)

         10. Need for systemic corticosteroids or any other medication that would influence
             post-operative healing and/or osseointegration

         11. History of radiation in the head and neck region

         12. Subject is pregnant as reported at time of enrollment

         13. Unable or unwilling to return for follow-up visits for a period of 6 months

         14. Unlikely to be able to comply with study procedures according to Investigators
             judgement

         15. Previous enrollment or randomization of treatment in the present study

         16. Involvement in the planning/conduct of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Cook, DDS MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC School of Dentistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina School of Dentistry</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 11, 2015</study_first_submitted>
  <study_first_submitted_qc>March 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <results_first_submitted>May 29, 2019</results_first_submitted>
  <results_first_submitted_qc>May 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2019</results_first_posted>
  <last_update_submitted>September 12, 2019</last_update_submitted>
  <last_update_submitted_qc>September 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth, Edentulous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 11, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02387008/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GUIDOR® Membrane With FDBA</title>
          <description>Horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
GUIDOR® membrane with FDBA: horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA</description>
        </group>
        <group group_id="P2">
          <title>GUIDOR® Membrane Alone</title>
          <description>Horizontal bone augmentation with synthetic GUIDOR® membrane
GUIDOR® membrane: horizontal bone augmentation with synthetic GUIDOR® membrane</description>
        </group>
        <group group_id="P3">
          <title>Bio-Gide® Membrane With FDBA</title>
          <description>Xenograft BioGide® membrane + Freeze-dried Bone Allograft (FDBA)
Bio-Gide® membrane with FDBA: xenograft BioGide® membrane + FDBA</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No participants were randomized to the GUIDOR® Membrane Alone Arm</population>
      <group_list>
        <group group_id="B1">
          <title>GUIDOR® Membrane With FDBA</title>
          <description>Horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
GUIDOR® membrane with FDBA: horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA</description>
        </group>
        <group group_id="B2">
          <title>GUIDOR® Membrane Alone</title>
          <description>Horizontal bone augmentation with synthetic GUIDOR® membrane
GUIDOR® membrane: horizontal bone augmentation with synthetic GUIDOR® membrane</description>
        </group>
        <group group_id="B3">
          <title>Bio-Gide® Membrane With FDBA</title>
          <description>Xenograft BioGide® membrane + FDBA
Bio-Gide® membrane with FDBA: xenograft BioGide® membrane + FDBA</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dimensional Bone Changes at 6 Months</title>
        <description>Dimensional bone changes will assessed by calculating horizontal width and vertical height changes using data from DICOM images acquired by Cone beam computed tomography (CBCT).</description>
        <time_frame>6 months after treatment</time_frame>
        <population>Protocol-defined collection intervals were not achieved for any subjects enrolled; therefore, no data available for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>GUIDOR® Membrane With FDBA</title>
            <description>Horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
GUIDOR® membrane with FDBA: horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA</description>
          </group>
          <group group_id="O2">
            <title>GUIDOR® Membrane Alone</title>
            <description>Horizontal bone augmentation with synthetic GUIDOR® membrane
GUIDOR® membrane: horizontal bone augmentation with synthetic GUIDOR® membrane</description>
          </group>
          <group group_id="O3">
            <title>Bio-Gide® Membrane With FDBA</title>
            <description>Xenograft BioGide® membrane + FDBA
Bio-Gide® membrane with FDBA: xenograft BioGide® membrane + FDBA</description>
          </group>
        </group_list>
        <measure>
          <title>Dimensional Bone Changes at 6 Months</title>
          <description>Dimensional bone changes will assessed by calculating horizontal width and vertical height changes using data from DICOM images acquired by Cone beam computed tomography (CBCT).</description>
          <population>Protocol-defined collection intervals were not achieved for any subjects enrolled; therefore, no data available for this measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammation</title>
        <description>The presence or absence of soft tissue erythema within 3 mm from the crestal incision in the edentulous site will be visually assessed at post-operative evaluations.</description>
        <time_frame>7 days, 14 days, 28 days, 6 months</time_frame>
        <population>No participants were randomized to the GUIDOR® Membrane Alone Arm</population>
        <group_list>
          <group group_id="O1">
            <title>GUIDOR® Membrane With FDBA</title>
            <description>Horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
GUIDOR® membrane with FDBA: horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA</description>
          </group>
          <group group_id="O2">
            <title>GUIDOR® Membrane Alone</title>
            <description>Horizontal bone augmentation with synthetic GUIDOR® membrane
GUIDOR® membrane: horizontal bone augmentation with synthetic GUIDOR® membrane</description>
          </group>
          <group group_id="O3">
            <title>Bio-Gide® Membrane With FDBA</title>
            <description>Xenograft BioGide® membrane + FDBA
Bio-Gide® membrane with FDBA: xenograft BioGide® membrane + FDBA</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation</title>
          <description>The presence or absence of soft tissue erythema within 3 mm from the crestal incision in the edentulous site will be visually assessed at post-operative evaluations.</description>
          <population>No participants were randomized to the GUIDOR® Membrane Alone Arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inflammation Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammation Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infection</title>
        <description>The presence or absence of infection in the area of ridge augmentation will be assessed through visual evaluation and palpation. The presence of suppuration from the crestal incision or soft tissues adjacent to the localized ridge augmentation will be assessed through visual evaluation. Fluctuance in the area of the augmentation will be assessed through gentle palpation of the surgical site.</description>
        <time_frame>7 days, 14 days, 28 days, 6 months</time_frame>
        <population>No participants were randomized to the GUIDOR® Membrane Alone Arm</population>
        <group_list>
          <group group_id="O1">
            <title>GUIDOR® Membrane With FDBA</title>
            <description>Horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
GUIDOR® membrane with FDBA: horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA</description>
          </group>
          <group group_id="O2">
            <title>GUIDOR® Membrane Alone</title>
            <description>Horizontal bone augmentation with synthetic GUIDOR® membrane
GUIDOR® membrane: horizontal bone augmentation with synthetic GUIDOR® membrane</description>
          </group>
          <group group_id="O3">
            <title>Bio-Gide® Membrane With FDBA</title>
            <description>Xenograft BioGide® membrane + FDBA
Bio-Gide® membrane with FDBA: xenograft BioGide® membrane + FDBA</description>
          </group>
        </group_list>
        <measure>
          <title>Infection</title>
          <description>The presence or absence of infection in the area of ridge augmentation will be assessed through visual evaluation and palpation. The presence of suppuration from the crestal incision or soft tissues adjacent to the localized ridge augmentation will be assessed through visual evaluation. Fluctuance in the area of the augmentation will be assessed through gentle palpation of the surgical site.</description>
          <population>No participants were randomized to the GUIDOR® Membrane Alone Arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infection present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Membrane Exposure</title>
        <description>The presence of membrane exposure or soft tissue dehiscence will be visually assessed.</description>
        <time_frame>7 days, 14 days, 28 days, 6 months</time_frame>
        <population>No participants were randomized to the GUIDOR® Membrane Alone Arm</population>
        <group_list>
          <group group_id="O1">
            <title>GUIDOR® Membrane With FDBA</title>
            <description>Horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
GUIDOR® membrane with FDBA: horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA</description>
          </group>
          <group group_id="O2">
            <title>GUIDOR® Membrane Alone</title>
            <description>Horizontal bone augmentation with synthetic GUIDOR® membrane
GUIDOR® membrane: horizontal bone augmentation with synthetic GUIDOR® membrane</description>
          </group>
          <group group_id="O3">
            <title>Bio-Gide® Membrane With FDBA</title>
            <description>Xenograft BioGide® membrane + FDBA
Bio-Gide® membrane with FDBA: xenograft BioGide® membrane + FDBA</description>
          </group>
        </group_list>
        <measure>
          <title>Membrane Exposure</title>
          <description>The presence of membrane exposure or soft tissue dehiscence will be visually assessed.</description>
          <population>No participants were randomized to the GUIDOR® Membrane Alone Arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>membrane exposure or soft tissue dehiscencePresent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>membrane exposure or soft tissue dehiscence Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to the completion of trial, approximately 6 months.</time_frame>
      <desc>No participants were randomized to the GUIDOR® Membrane Alone Arm</desc>
      <group_list>
        <group group_id="E1">
          <title>GUIDOR® Membrane With FDBA</title>
          <description>Horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
GUIDOR® membrane with FDBA: horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA</description>
        </group>
        <group group_id="E2">
          <title>GUIDOR® Membrane Alone</title>
          <description>Horizontal bone augmentation with synthetic GUIDOR® membrane
GUIDOR® membrane: horizontal bone augmentation with synthetic GUIDOR® membrane</description>
        </group>
        <group group_id="E3">
          <title>Bio-Gide® Membrane With FDBA</title>
          <description>Xenograft BioGide® membrane + FDBA
Bio-Gide® membrane with FDBA: xenograft BioGide® membrane + FDBA</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Slow progression of recruitment and consequent enrollment of only 6 out of 60 planned participants lead to study termination and insufficient data to provide a substantive analysis. Thus data analysis was not performed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gidgetta Kang</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-537-3968</phone>
      <email>gidget_jenkins@unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

